Cogent Biosciences Inc近日宣布，美国食品药品监督管理局（FDA）已正式受理其新药Bezuclastinib用于治疗非晚期系统性肥大细胞增多症（Nonadvsm）的上市申请。根据FDA的处方药使用者付费法案（PDUFA），该药物的审评截止日期定为2026年12月30日。
Cogent Biosciences Inc近日宣布，美国食品药品监督管理局（FDA）已正式受理其新药Bezuclastinib用于治疗非晚期系统性肥大细胞增多症（Nonadvsm）的上市申请。根据FDA的处方药使用者付费法案（PDUFA），该药物的审评截止日期定为2026年12月30日。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.